Neogenomics (NEO) Accumulated Expenses (2010 - 2026)

Neogenomics has reported Accumulated Expenses for 17 years, with the latest figure at $12.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 67.77% year-over-year to $12.7 million; the trailing twelve-month figure through Mar 2026 stood at $12.7 million (down 67.77% YoY), and the FY2025 full-year result was $47.6 million, down 23.8% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $12.7 million, down from $47.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $62.4 million in Q4 2024, with the low at $12.7 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $35.6 million across 5 years, with a median of $38.0 million in 2022.
• Annual changes were most pronounced in 2023 — Accumulated Expenses soared 252.76% — and 2026, when it plunged 67.77%.
• Neogenomics' Accumulated Expenses stood at $15.1 million in 2022, then soared by 252.76% to $53.2 million in 2023, then increased by 17.46% to $62.4 million in 2024, then slipped by 23.8% to $47.6 million in 2025, then tumbled by 73.25% to $12.7 million in 2026.
• The last three Accumulated Expenses figures came in at $12.7 million (Q1 2026), $47.6 million (Q4 2025), and $17.4 million (Q3 2025), per Business Quant data.